HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide

The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloabla...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Bacigalupo, Simona Sica
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Advances in Hematology
Online Access:http://dx.doi.org/10.1155/2016/7802967
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of high dose posttransplant cyclophosphamide (PT-CY) introduced by the Baltimore group approximately 10 years ago has been rapidly adopted worldwide and is becoming a standard for patients undergoing unmanipulated haploidentical (HAPLO) transplants. PT-CY has been used following nonmyeloablative as well as myeloablative conditioning regimens, for bone marrow or peripheral blood grafts, for patients with malignant and nonmalignant disorders. Retrospective comparisons of HAPLO grafts with conventional sibling and unrelated donor grafts have been published and suggest comparable outcome. The current questions to be answered include the use of PT-CY for sibling and unrelated donors transplant, possibly in the context of prospective randomized trial.
ISSN:1687-9104
1687-9112